How do the treatment guidelines for acute myeloid leukemia (AML) of the National Comprehensive Cancer Network (NCCN) differ from those of the European Society of Medical Oncology (ESMO)?

Updated: May 26, 2020
  • Author: Karen Seiter, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print

The NCCN guidelines give detailed recommendations based on patient characteristics such as age, presence of comorbid conditions affecting performance status, and preexisting myelodysplasia. Among the recommendations is that patients with poor performance status, significant comorbities, and/or advanced age (ie, some patients ≥ 60 years old and most patients ≥ 70 years old) should receive low-intensity therapy or supportive care if a clinical trial is not available. [25]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!